Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 4.460-4.460 for the period, compared to the consensus EPS estimate of 4.490. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PBH. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $77.44 on Thursday. The firm has a 50-day moving average of $72.31 and a 200-day moving average of $69.71. Prestige Consumer Healthcare has a one year low of $56.61 and a one year high of $79.25. The company has a market cap of $3.84 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.47. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The company’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.06 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.43 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.